{"nctId":"NCT01305200","briefTitle":"Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant","startDateStruct":{"date":"2011-03"},"conditions":["Childhood Acute Lymphoblastic Leukemia in Remission","Childhood Acute Myeloid Leukemia in Remission","Childhood Chronic Myelogenous Leukemia","Childhood Myelodysplastic Syndromes","Chronic Eosinophilic Leukemia","Chronic Myelomonocytic Leukemia","Chronic Neutrophilic Leukemia","de Novo Myelodysplastic Syndromes","Disseminated Neuroblastoma","Juvenile Myelomonocytic Leukemia","Mucositis","Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable","Previously Treated Childhood Rhabdomyosarcoma","Previously Treated Myelodysplastic Syndromes","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Large Cell Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent Childhood Rhabdomyosarcoma","Recurrent Childhood Small Noncleaved Cell Lymphoma","Recurrent Malignant Testicular Germ Cell Tumor","Recurrent Wilms Tumor and Other Childhood Kidney Tumors","Recurrent/Refractory Childhood Hodgkin Lymphoma","Relapsing Chronic Myelogenous Leukemia","Secondary Acute Myeloid Leukemia","Secondary Myelodysplastic Syndromes","Unspecified Childhood Solid Tumor, Protocol Specific"],"count":226,"armGroups":[{"label":"Arm I (placebo)","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo","Other: questionnaire administration","Procedure: quality-of-life assessment"]},{"label":"Arm II (supersaturated calcium phosphate rinse)","type":"EXPERIMENTAL","interventionNames":["Drug: supersaturated calcium phosphate rinse","Other: questionnaire administration","Procedure: quality-of-life assessment"]}],"interventions":[{"name":"supersaturated calcium phosphate rinse","otherNames":["Caphosol"]},{"name":"placebo","otherNames":["PLCB"]},{"name":"questionnaire administration","otherNames":[]},{"name":"quality-of-life assessment","otherNames":["quality of life assessment"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients undergoing myeloablative autologous or allogeneic hematopoietic stem cell transplantation (HSCT) for any indication\n* One or more of the following donor stem cell sources (autologous or allogeneic):\n\n  * Bone marrow\n  * Placental blood (umbilical cord blood)\n  * Cytokine-mobilized peripheral blood\n* Patients eligible for allogeneic HSCT must have one of the following types of donor stem cells:\n\n  * Human leukocyte antigen (HLA)-matched sibling or parent\n  * Partially matched family donor (mismatched for a single HLA locus \\[Class I\\])\n  * Fully matched unrelated marrow or peripheral blood stem cell donor\n  * HLA-matched or partially mismatched (at least 4 of 6 match) cord blood (Class I or II)\n* Patients expecting to receive any type of myeloablative HSCT conditioning regimen are eligible\n\n  * No non-myeloablative or reduced-intensity conditioning regimens\n* Eligible patients must not have received palifermin within 30 days prior to enrollment\n* Eligible patients must not have received prior treatment with Caphosol\n\nExclusion Criteria:\n\n* Females of childbearing potential must have a negative pregnancy test; patients must agree to use an effective birth control method; lactating patients must agree not to nurse a child while on this trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Severe Oral Mucositis (WHO Grade 3 or 4)","description":"Mean days of severe (WHO Grade 3 or 4) Mucositis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"4.8"},{"groupId":"OG001","value":"4.5","spread":"5"}]}]}]},{"type":"SECONDARY","title":"Incidence of Severe Oral Mucositis","description":"Percentage of patients with Severe Oral Mucositis (WHO Grade 3 or 4) per arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Oral Mucositis Daily Questionnaire (OMDQ)","description":"Area under the curve (AUC) of the Oral Mucositis Daily Questionnaire (OMDQ) subscales","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":"10.9"},{"groupId":"OG001","value":"7.3","spread":"9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":"14.8"},{"groupId":"OG001","value":"21.4","spread":"14.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":"15.7"},{"groupId":"OG001","value":"19.9","spread":"15.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","spread":"16.3"},{"groupId":"OG001","value":"20.6","spread":"17.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","spread":"19.4"},{"groupId":"OG001","value":"26.6","spread":"20.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"11.5"},{"groupId":"OG001","value":"12","spread":"13.2"}]}]}]},{"type":"SECONDARY","title":"Incidence of Parenteral Opioid Analgesic Use (Morphine Equivalents).","description":"Opioid Administration = yes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.7","spread":null},{"groupId":"OG001","value":"91.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Parenteral Opioid Analgesic Use (Morphine Equivalents).","description":"Mean days of parenteral opioid analgesic use.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":"9.5"},{"groupId":"OG001","value":"12.5","spread":"8.7"}]}]}]},{"type":"SECONDARY","title":"Total Dose of Parenteral Opioid Analgesic Used (Morphine Equivalents).","description":"Morphine equivalent dose in mg/kg/day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Total Parenteral Nutrition (TPN) Administration.","description":"Total Parenteral Nutrition = yes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":null},{"groupId":"OG001","value":"72.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Total Parenteral Nutrition (TPN) Administration.","description":"Mean days of total parenteral nutrition (TPN) administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":"9.9"},{"groupId":"OG001","value":"11.4","spread":"8.9"}]}]}]},{"type":"SECONDARY","title":"Incidence of Febrile Neutropenia","description":"Fever and Neutropenia = yes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.1","spread":null},{"groupId":"OG001","value":"67.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Invasive Bacterial Infections","description":"Invasive Bacterial Infection = yes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Mucositis","description":"Area Under the Curve of Severity of Mucositis. According to mouth pain categorical rating scale ranges 0-10 with higher scores reflecting more severe pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":"36"},{"groupId":"OG001","value":"44","spread":"35.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Ancillary Validation Study of ChIMES","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":106},"commonTop":["Oral pain","Infections and infestations - Other, specify","Dysgeusia","Allergic reaction","Anaphylaxis"]}}}